BioAtla Inc (NAS:BCAB)
$ 2.05 0.3 (17.14%) Market Cap: 98.64 Mil Enterprise Value: 5.50 Mil PE Ratio: 0 PB Ratio: 1.99 GF Score: 35/100

Q4 2022 Bioatla Inc Earnings Call Transcript

Mar 23, 2023 / 08:30PM GMT
Release Date Price: $2.3 (-1.71%)
Operator

Greetings, and welcome to the BioAtla Fourth Quarter and Full Year 2022 Earnings Call. (Operator Instructions) Please note, this conference is being recorded. I will now turn the conference over to your host, Bruce Mackle. You may begin.

Bruce Mackle

Thank you, operator, and good afternoon, everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO and Co-Founder; Richard Waldron, Chief Financial Officer. And following today's call, Philippe Martin, Chief of Clinical Development and Operations; Eric Sievers, Chief Medical Officer; and Sheri Lydick, Senior Vice President, Commercial Strategy will join Jay and Rick for a short Q&A.

Earlier this afternoon, BioAtla released financial results and a business update for the fourth quarter and full year ended December 31, 2022. A copy of the press release is available on the company's website.

Before we begin, I'd like to remind everyone that statements made during this conference call will include forward-looking statements, including, but not limited to, statements regarding

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot